Earnings Call Summary | ICAD Inc(ICAD.US) Q1 2024 Earnings Conference
Earnings Call Summary | ICAD Inc(ICAD.US) Q1 2024 Earnings Conference
The following is a summary of the ICAD, Inc. (ICAD) Q1 2024 Earnings Call Transcript:
以下是ICAD公司（ICAD）2024年第一季度業績電話會議記錄的摘要：
Financial Performance:
財務業績：
iCAD reported a 14% increase in Q1 2024 revenue compared to Q1 2023, amounting to $5 million.
Product revenue rose by 26% to $3.1 million, while service revenue remained steady at $1.9 million.
Gross profit for Q1 2024 was $4.1 million or 83% of revenue, a rise from 82% in Q1 2023.
The GAAP net loss was reduced to $1.2 million in Q1 2024, from a net loss of $3.1 million in Q1 2023.
The non-GAAP adjusted EBITDA loss was also reduced in the first quarter of 2024 compared to the same period in 2023.
The company had $20.3 million in cash and cash equivalents as of March 31, 2024.
iCad報告稱，與2023年第一季度相比，2024年第一季度的收入增長了14％，達到500萬美元。
產品收入增長了26％，達到310萬美元，而服務收入穩定在190萬美元。
2024年第一季度的毛利爲410萬美元，佔收入的83％，高於2023年第一季度的82％。
GAAP淨虧損從2023年第一季度的310萬美元淨虧損減少至2024年第一季度的120萬美元。
與2023年同期相比，2024年第一季度非公認會計准則調整後的息稅折舊攤銷前利潤虧損也有所減少。
截至2024年3月31日，該公司擁有2,030萬美元的現金及現金等價物。
Business Progress:
業務進展：
iCAD completed phases 1 and 2 of their transformation plan and commenced phase 3, focusing on expanding into key accounts and new markets.
The company hired new sales reps and appointed Peter Graham as Head of North American Sales in Q1 2024.
Significant deals were secured with several companies including Dignity Health, Raleigh Radiology, and Northern Navajo.
The company successfully expanded globally, with notable progress in Eastern Europe, and made their ProFound Cloud platform commercially available.
Dr. Hedvig Hricak and Mike Doyle joined the Board of Directors, contributing their extensive experience in healthcare technology and business strategy.
The company collaborated with RAD-AID International to offer AI-based decision support in mammography in Guyana.
The company has shifted to a recurring revenue model and currently has sufficient resources for operations without additional funding.
The company has begun tracking total orders including perpetual product and subscription orders and is focusing more on new business, lead generation, pricing models, and customer retention. An FDA approval for 4.0 and heart health is expected by the end of calendar year.
iCad完成了轉型計劃的第一和第二階段，並開始了第三階段，重點是向關鍵客戶和新市場擴張。
該公司聘請了新的銷售代表，並任命彼得·格雷厄姆爲2024年第一季度北美銷售主管。
與包括Dignity Health、Raleigh Radiology和Northern Navajo在內的多家公司達成了重大協議。
該公司成功地向全球擴張，在東歐取得了顯著進展，並將他們的InfOrandCloud平台投入商用。
Hedvig Hricak博士和Mike Doyle博士加入了董事會，貢獻了他們在醫療技術和業務戰略方面的豐富經驗。
該公司與RAD-AID International合作，爲圭亞那的乳房X光檢查提供基於人工智能的決策支持。
該公司已轉向經常性收入模式，目前無需額外資金即可擁有足夠的運營資源。
該公司已開始跟蹤包括永久產品和訂閱訂單在內的總訂單，並將更多精力放在新業務、潛在客戶生成、定價模式和客戶保留率上。預計到日曆年年底，美國食品藥品管理局將批准4.0和心臟健康。
More details: iCAD Inc IR
更多詳情： iCad Inc IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。